1 |
SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29.
|
2 |
HUA Z, WHITE J, ZHOU J J. Cancer stem cells in TNBC[J]. Semin Cancer Biol, 2022, 82: 26-34.
|
3 |
BROOKS M D, BURNESS M L, WICHA M S. Therapeutic implications of cellular heterogeneity and plasticity in breast cancer[J]. Cell Stem Cell, 2015, 17(3): 260-271.
|
4 |
JARROLD J, DAVIES C C. PRMTs and arginine methylation: cancer's best-kept secret?[J]. Trends Mol Med, 2019, 25(11): 993-1009.
|
5 |
BEDFORD M T, RICHARD S. Arginine methylation an emerging regulator of protein function[J]. Mol Cell, 2005, 18(3): 263-272.
|
6 |
BLANC R S, RICHARD S. Arginine methylation: the coming of age[J]. Mol Cell, 2017, 65(1): 8-24.
|
7 |
STOPA N, KREBS J E, SHECHTER D. The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond[J]. Cell Mol Life Sci, 2015, 72(11): 2041-2059.
|
8 |
KIM S, KIM N H, PARK J E, et al. PRMT6-mediated H3R2me2a guides Aurora B to chromosome arms for proper chromosome segregation[J]. Nat Commun, 2020, 11(1): 612.
|
9 |
HUANG T Z, YANG Y Y, SONG X, et al. PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells[J]. Mol Cell, 2021, 81(6): 1276-1291.e9.
|
10 |
WONG T L, NG K Y, TAN K V, et al. CRAF methylation by PRMT6 regulates aerobic glycolysis-driven hepatocarcinogenesis via ERK-dependent PKM2 nuclear relocalization and activation[J]. Hepatology, 2020, 71(4): 1279-1296.
|
11 |
YANG T S, HUANG W, MA T Y, et al. The PRMT6/PARP1/CRL4B complex regulates the circadian clock and promotes breast tumorigenesis[J]. Adv Sci, 2023, 10(14): e2202737.
|
12 |
MONTALTO F I, DE AMICIS F. Cyclin D1 in cancer: a molecular connection for cell cycle control, adhesion and invasion in tumor and stroma[J]. Cells, 2020, 9(12): 2648.
|
13 |
YU Q, GENG Y, SICINSKI P. Specific protection against breast cancers by cyclin D1 ablation[J]. Nature, 2001, 411(6841): 1017-1021.
|
14 |
FONTANA R, MESTRE-FARRERA A, YANG J. Update on epithelial-mesenchymal plasticity in cancer progression[J]. Annu Rev Pathol, 2024, 19: 133-156.
|
15 |
GUPTA S, KADUMURI R V, SINGH A K, et al. Structure, activity and function of the protein arginine methyltransferase 6[J]. Life (Basel), 2021, 11(9): 951.
|
16 |
LUO Y H, XIE C, BROCKER C N, et al. Intestinal PPARα protects against colon carcinogenesis via regulation of methyltransferases DNMT1 and PRMT6[J]. Gastroenterology, 2019, 157(3): 744-759.e4.
|
17 |
ALMEIDA-RIOS D, GRAÇA I, VIEIRA F Q, et al. Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer[J]. Oncotarget, 2016, 7(33): 53018-53028.
|
18 |
OKUNO K, AKIYAMA Y, SHIMADA S, et al. Asymmetric dimethylation at histone H3 arginine 2 by PRMT6 in gastric cancer progression[J]. Carcinogenesis, 2019, 40(1): 15-26.
|
19 |
STEIN C, RIEDL S, RÜTHNICK D, et al. The arginine methyltransferase PRMT6 regulates cell proliferation and senescence through transcriptional repression of tumor suppressor genes[J]. Nucleic Acids Res, 2012, 40(19): 9522-9533.
|
20 |
WANG J, SU W, ZHANG T T, et al. Aberrant cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation[J]. Cell Death Dis, 2023, 14(4): 244.
|
21 |
SCHNEIDER L, HERKT S, WANG L, et al. PRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1[J]. Oncogenesis, 2021, 10(5): 42.
|
22 |
MITCHELL L H, DREW A E, RIBICH S A, et al. Aryl pyrazoles as potent inhibitors of arginine methyltransferases: identification of the first PRMT6 tool compound[J]. ACS Med Chem Lett, 2015, 6(6): 655-659.
|